八钙磷酸盐/明胶复合物(OCP/Gel)促进大鼠股骨临界尺寸经皮质骨缺损的骨修复
研究使用34只12周龄雄性Sprague-Dawley大鼠建立股骨3 mm经皮质临界尺寸骨缺损模型,比较OCP/Gel与明胶海绵(Gel)对照的骨再生效果。Micro-CT、组织学及免疫染色显示,OCP/Gel组在4周和8周的新生骨量、新生骨百分比、成熟成骨细胞数及破骨细胞样细胞数均高于Gel组。结论提示OCP/Gel可较早诱导骨重塑和皮质骨修复,作者认为其可能作为骨替代材料用于治疗严重骨缺损。
要点
- OCP/Gel组4周和8周micro-CT新生骨体积均高于Gel组,差异有统计学意义。
- OCP/Gel组4周和8周组织学新生骨百分比均高于Gel组,差异有统计学意义。
- OCP/Gel组4周成熟成骨细胞数和破骨细胞样细胞数均高于Gel组。
核心结论
- 在大鼠股骨临界尺寸经皮质骨缺损模型中,OCP/Gel复合物较Gel对照在更短时间内诱导早期骨重塑和皮质骨修复,提示OCP/Gel可能作为骨替代材料用于治疗严重骨缺损。
研究设计与样本
- 研究使用34只12周龄雄性Sprague-Dawley大鼠(体重356 ± 25.6 g),将直径3 mm、高4 mm的多孔圆柱体植入左股骨3 mm经皮质临界尺寸骨缺损模型,OCP/Gel与Gel随机分配植入。
- 植入后4周和8周进行CT评估、脱钙样本组织学检查及免疫染色定量分析(n = 24),植入后3周对未脱钙样本进行定性组织学评估(n = 10)。
- CT和脱钙组织分析未设盲,未脱钙样本分析在设盲条件下进行。
主要发现
- Micro-CT新生骨体积:4周时OCP/Gel组6.1 ± 1.6 mm³ vs Gel组3.4 ± 0.7 mm³,平均差2.7(95%CI 0.9至4.5),p = 0.002,ICC 0.72(95%CI 0.29至0.91)。
- Micro-CT新生骨体积:8周时OCP/Gel组3.9 ± 0.7 mm³ vs Gel组1.4 ± 1.1 mm³,平均差2.5(95%CI 0.8至4.3),p = 0.004,ICC 0.81(95%CI 0.47至0.94)。
- 组织学新生骨百分比:4周时OCP/Gel组31.2% ± 5.3% vs Gel组13.6% ± 4.0%,平均差17.6%(95%CI 14.2%至29.2%),p < 0.001,ICC 0.83(95%CI 0.53至0.95)。
- 组织学新生骨百分比:8周时OCP/Gel组28.3% ± 6.2% vs Gel组9.5% ± 1.9%,平均差18.8%(95%CI 11.3%至26.3%),p < 0.001,ICC 0.90(95%CI 0.69至0.97)。
- 4周时OCP/Gel组成熟成骨细胞数42.1 ± 6.5/mm² vs Gel组17.4 ± 5.4/mm²,平均差24.7(95%CI 16.2至33.2),p < 0.001,ICC 0.99(95%CI 0.97至0.99);OCP/Gel组破骨细胞样细胞数3.2 ± 0.6/mm² vs Gel组0.9 ± 0.4/mm²,平均差2.3(95%CI 1.3至3.5),p < 0.001,ICC 0.79(95%CI 0.35至0.94)。
临床怎么用
- 作者认为,OCP/Gel复合物在大鼠股骨临界尺寸经皮质骨缺损模型中成功实现骨再生,可能作为骨替代材料用于治疗严重骨缺损。
- 作者指出,未来需要多项研究评估该骨移植替代物的临床应用,包括在难治性骨折和脊柱融合模型中的骨形成能力,以及OCP/Gel复合物修复后骨强度与自体骨的比较。
局限性
- CT和脱钙组织分析未设盲,未脱钙样本分析在设盲条件下进行。
- 作者指出,未来需要多项研究评估该骨移植替代物的临床应用,包括在难治性骨折和脊柱融合模型中的骨形成能力,以及OCP/Gel复合物修复后骨强度与自体骨的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone grafting is widely used to treat large bone defects. A porous composite of a bioactive octacalcium phosphate material with gelatin sponge (OCP/Gel) has been shown to biodegrade promptly and be replaced with new bone both in animal models of a membranous bone defect and a long bone defect. However, it is unclear whether OCP/Gel can regenerate bone in more severe bone defects, such as a critical-size transcortical defect. QUESTIONS/PURPOSES: Using an in vivo rat femur model of a standardized, transcortical, critical-size bone defect, we asked: Compared with a Gel control, does OCP/Gel result in more newly formed bone as determined by (1) micro-CT evaluation, (2) histologic and histomorphometric measures, and (3) osteocalcin staining and tartrate-resistant acid phosphatase staining? METHODS: Thirty-four 12-week-old male Sprague-Dawley rats (weight 356 ± 25.6 g) were used. Gel and OCP/Gel composites were prepared in our laboratory. Porous cylinders 3 mm in diameter and 4 mm in height were manufactured from both materials. The OCP/Gel and Gel cylinders were implanted into a 3-mm-diameter transcortical critical-size bone defect model in the left rat femur. The OCP/Gel and Gel were randomly assigned, and the cylinders were implanted. The biological responses of the defect regions were evaluated radiologically and histologically. At 4 and 8 weeks after implantation, CT evaluation, histological examination of decalcified samples, and immunostaining were quantitatively performed to evaluate new bone formation and remaining bone graft substitutes and activity of osteoblasts and osteoclast-like cells (n = 24). Qualitative histological evaluation was performed on undecalcified samples at 3 weeks postimplantation (n = 10). CT and decalcified tissue analysis was not performed blinded, but an analysis of undecalcified specimens was performed under blinded conditions. RESULTS: Radiologic analysis revealed that the OCP/Gel group showed radiopaque regions around the OCP granules and at the edge of the defect margin 4 weeks after implantation, suggesting that new bone formation occurred in two ways. In contrast, the rat femurs in the Gel group had a limited radiopaque zone at the edge of the defect region. The amount of new bone volume analyzed by micro-CT was higher in the OCP/Gel group than in the Gel group at 4 and 8 weeks after implantation (4 weeks after implantation: OCP/Gel versus Gel: 6.1 ± 1.6 mm 3 versus 3.4 ± 0.7 mm 3 , mean difference 2.7 [95% confidence interval (CI) 0.9 to 4.5]; p = 0.002; intraclass correlation coefficient [ICC] 0.72 [95% CI 0.29 to 0.91]; 8 weeks after implantation: OCP/Gel versus Gel: 3.9 ± 0.7 mm 3 versus 1.4 ± 1.1 mm 3 , mean difference 2.5 [95% CI 0.8 to 4.3]; p = 0.004; ICC 0.81 [95% CI 0.47 to 0.94]). Histologic evaluation also showed there was a higher percentage of new bone formation in the OCP/Gel group at 4 and 8 weeks after implantation (4 weeks after implantation: OCP/Gel versus Gel: 31.2% ± 5.3% versus 13.6% ± 4.0%, mean difference 17.6% [95% CI 14.2% to 29.2%]; p < 0.001; ICC 0.83 [95% CI 0.53 to 0.95]; 8 weeks after implantation: OCP/Gel versus Gel: 28.3% ± 6.2% versus 9.5% ± 1.9%, mean difference 18.8% [95% CI 11.3% to 26.3%]; p < 0.001; ICC 0.90 [95% CI 0.69 to 0.97]). Bridging of the defect area started earlier in the OCP/Gel group than in the Gel group at 4 weeks after implantation. Osteocalcin immunostaining showed that the number of mature osteoblasts was higher in the OCP/Gel group than in the Gel group at 4 weeks (OCP/Gel versus Gel: 42.1 ± 6.5/mm 2 versus 17.4 ± 5.4/mm 2 , mean difference 24.7 [95% CI 16.2 to 33.2]; p < 0.001; ICC 0.99 [95% CI 0.97 to 0.99]). At 4 weeks, the number of osteoclast-like cells was higher in the OCP/Gel composite group than in the Gel group (OCP/Gel versus Gel: 3.2 ± 0.6/mm 2 versus 0.9 ± 0.4/mm 2 , mean difference 2.3 [95% CI 1.3 to 3.5]; p < 0.001; ICC 0.79 [95% CI 0.35 to 0.94]). CONCLUSION: OCP/Gel composites induced early bone remodeling and cortical bone repair in less time than did the Gel control in a rat critical-size, transcortical femoral defect, suggesting that OCP/Gel could be used as a bone replacement material to treat severe bone defects. CLINICAL RELEVANCE: In a transcortical bone defect model of critical size in the rat femur, the OCP/Gel composite demonstrated successful bone regeneration. Several future studies are needed to evaluate the clinical application of this interesting bone graft substitute, including bone formation capacity in refractory fracture and spinal fusion models and the comparison of bone strength after repair with OCP/Gel composite to that of autologous bone.
引用
- Hamada S, Mori Y, Shiwaku Y, et al. Octacalcium Phosphate/Gelatin Composite (OCP/Gel) Enhances Bone Repair in a Critical-sized Transcortical Femoral Defect Rat Model. Clin Orthop Relat Res. 2022. PMID: 35638896. doi:10.1097/CORR.0000000000002257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。